Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq:
TERN), a clinical-stage biopharmaceutical company developing a
portfolio of small-molecule product candidates to address serious
diseases, including oncology and obesity, today announced that
management will provide an update on its pipeline and strategic
priorities for 2024 during the Company’s presentation at the 42nd
Annual J.P. Morgan Healthcare Conference on January 10th, 2024 at
1:30pm PT.
“2023 was a highly productive year for Terns as we made
significant strides towards achieving our mission to bring better,
novel medicines to people living with diseases of significant unmet
medical need. We are proud to have fully achieved our stated
corporate objectives last year, including initiating two
proof-of-concept trials in CML and obesity, reporting positive
Phase 2a data for NASH, publishing supportive preclinical data in
oncology, hosting educational webinars with leading KOLs in CML and
obesity, and advancing important discovery efforts within obesity,”
said Erin Quirk, M.D., president and head of R&D of Terns. “We
expect 2024 to be a compelling year for Terns as we read out early
proof-of-concept data for CML and obesity in the second half of
this year.”
“Terns’ rigorous capital allocation decisions continue to be
informed and driven by emerging data and the development landscape
for our programs,” said Mark Vignola, Ph.D., chief financial
officer of Terns. “As we move into 2024, we are prioritizing
capital allocation towards our oncology and obesity programs, while
limiting near-term development spend on TERN-501 in NASH. Based on
the potential best-in-class efficacy and safety profile shown in
the Phase 2a DUET trial, we remain encouraged by the potential of
TERN-501 beyond NASH, particularly in obesity, where we believe it
could have a meaningful treatment benefit in combination with other
therapies. We will continue to evaluate the evolving NASH
landscape, including any substantive changes to regulatory and
development pathways, as we consider future opportunities for
TERN-501.”
Anticipated 2024 Priorities and Key
Milestones
TERN-701: Oral, allosteric BCR-ABL tyrosine kinase inhibitor
(TKI) for chronic myeloid leukemia (CML)
- Terns initiated the CARDINAL Phase 1
trial and screening is underway
- Trial progressing with site
activations globally and study-eligible subjects being identified
by investigators for potential study participation
- The CARDINAL study design leverages
insights from the ongoing Phase 1 trial in China, which support a
starting dose that appears safe and clinically active based on
emerging early clinical data
- The CARDINAL trial design features
multiple advantages to differentiate TERN-701 in the CML treatment
landscape
- Opportunity to efficiently develop
TERN-701 as a dose-optimized allosteric inhibitor for CML
- Inclusion of second-line (2L)
chronic phase CML patients better positions Terns to potentially
move directly to a 2L (or earlier line) pivotal study
- Reduced competition for trial
enrollment as no allosteric inhibitor is currently approved for 2L
CML patients
- Interim data from initial CARDINAL
dose escalation cohorts are expected in 2H24
TERN-601: Oral, small-molecule glucagon-like peptide-1 (GLP-1)
receptor agonist for obesity
- Phase 1 first-in-human clinical
trial of Terns’ lead oral GLP-1 receptor agonist in obese and
overweight participants remains ongoing and is on track to report
top-line data in 2H24
- Primary endpoints include safety and
tolerability assessments
- Secondary and exploratory endpoints
include PK and change in body weight over 28 days
- Terns continues preclinical efforts
to identify promising oral, small molecule combination candidates
for obesity (e.g., GLP-1 + THR-b, GLP-1 + GIPR agonist /
antagonist)
TERN-501: Oral, thyroid hormone receptor-beta (THR-β)
agonist
- The Phase 2a DUET trial
(NCT05415722) produced positive top-line data in August 2023;
showing compelling MRI-PDFF reductions and best-in-class safety and
tolerability profile with TERN-501 in NASH
- TERN-501 is a THR-β agonist with
high metabolic stability, enhanced liver distribution and greater
selectivity for THR-β compared to other THR-β agonists in
development
- Terns has decided to limit spend in
NASH given the current regulatory and clinical development
requirements for the indication
- No additional capital has been
allocated to future TERN-501 trials in NASH
- Terns will continue to evaluate
opportunities for TERN-501, including in other metabolic diseases,
with a focus towards combination regimens for obesity
TERN-800 Series: Oral, small molecule glucose-dependent
insulinotropic polypeptide receptor (GIPR) modulators
- Discovery efforts are ongoing for
the TERN-800 series of small molecule GIPR modulators for
obesity
- GIPR modulators have the potential
for combination with GLP-1 receptor agonists, such as TERN-601
A live webcast of the Company’s J.P. Morgan Healthcare
Conference presentation will be available on the investor relations
page of Terns’ website at http://ir.ternspharma.com. A replay
of the webcast will be archived on Terns’ website for 30 days
following the presentation.
About Terns PharmaceuticalsTerns
Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company
developing a portfolio of small-molecule product candidates to
address serious diseases, including oncology and obesity. Terns’
pipeline includes three clinical stage development programs
including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1
receptor agonist, a THR-β agonist and preclinical GIPR modulator
programs. For more information, please
visit: www.ternspharma.com.
Cautionary Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements about Terns Pharmaceuticals, Inc. (the “Company,” “we,”
“us,” or “our”) within the meaning of the federal securities laws,
including those related to the Company’s expectations of timing and
potential results of the clinical trials and other development
activities of the Company and its partners; the potential
indications to be targeted by the Company with its small-molecule
product candidates; the therapeutic potential of the Company’s
small-molecule product candidates; the potential for the mechanisms
of action of the Company’s product candidates to be therapeutic
targets for their targeted indications; the potential utility and
progress of the Company’s product candidates in their targeted
indications, including the clinical utility of the data from and
the endpoints used in the Company’s clinical trials; the Company’s
clinical development plans and activities; the Company’s
expectations regarding the profile of its product candidates,
including efficacy, tolerability, safety, metabolic stability and
pharmacokinetic profile and potential differentiation as compared
to other products or product candidates; the Company’s plans for
and ability to continue to execute on its current development
strategy, including potential combinations involving multiple
product candidates; and the Company’s expectations with regard to
its cash runway and sufficiency of its cash resources. All
statements other than statements of historical facts contained in
this press release, including statements regarding the Company’s
strategy, future financial condition, future operations, future
trial results, projected costs, prospects, plans, objectives of
management and expected market growth, are forward-looking
statements. In some cases, you can identify forward-looking
statements by terminology such as “aim,” “anticipate,” “assume,”
“believe,” “contemplate,” “continue,” “could,” “design,” “due,”
“estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,”
“positioned,” “potential,” “predict,” “seek,” “should,” “target,”
“will,” “would” and other similar expressions that are predictions
of or indicate future events and future trends, or the negative of
these terms or other comparable terminology. The Company has based
these forward-looking statements largely on its current
expectations, estimates, forecasts and projections about future
events and financial trends that it believes may affect its
financial condition, results of operations, business strategy and
financial needs. In light of the significant uncertainties in these
forward-looking statements, you should not rely upon
forward-looking statements as predictions of future events. These
statements are subject to risks and uncertainties that could cause
the actual results and the implementation of the Company’s plans to
vary materially, including the risks associated with the
initiation, cost, timing, progress, results and utility of the
Company’s current and future research and development activities
and preclinical studies and clinical trials. These risks are not
exhaustive. For a detailed discussion of the risk factors that
could affect the Company’s actual results, please refer to the risk
factors identified in the Company’s SEC reports, including but not
limited to its Annual Report on Form 10-K for the year ended
December 31, 2022 and its Quarterly Report on Form 10-Q for the
periods ended March 31, 2023, June 30, 2023 and September 30, 2023.
Except as required by law, the Company undertakes no obligation to
update publicly any forward-looking statements for any reason.
Contacts for Terns
InvestorsJustin Nginvestors@ternspharma.com
MediaJenna UrbanBerry & Company Public
Relationsmedia@ternspharma.com
Terns Pharmaceuticals (NASDAQ:TERN)
過去 株価チャート
から 8 2024 まで 9 2024
Terns Pharmaceuticals (NASDAQ:TERN)
過去 株価チャート
から 9 2023 まで 9 2024